Author’s response to reviews

Title: The combination of four molecular markers improves thyroid cancer cytologic diagnosis and patient management

Authors:

Federica Panebianco (panebiancof@upmc.edu)
Chiara Mazzanti (c.mazzanti@fondazionepisascienza.org)
Sara Tomei (stomei@sidra.org)
Paolo Aretini (p.aretini@fondazionepisascienza.org)
Sara Franceschi (sara.franceschi@fondazionepisascienza.org)
Francesca Lessi (f.lessi@fondazionepisascienza.org)
Giancarlo Di Coscio (g.dicoscio@ao-pisa.toscana.it)
Generoso Bevilacqua (generoso.bevilacqua@med.unipi.it)
Ivo Marchetti (i.marchetti@ao-pisa.toscana.it)

Version: 5 Date: 16 October 2015

Author’s response to reviews: see over
Dear Editor,

Please find included the final version of the manuscript entitled “Combination of four molecular markers improves thyroid cancer cytologic diagnosis and patients management” by Panebianco et al. for publication in BMC Cancer, Translational Oncology Section (MS:1840605813168730).

As required by the Editor, we specified in the Methods section, Ethics paragraph, the reason for the verbal consent. In fact, all patients verbally gave their informed consent before thyroid cells were collected. The verbal consent consisted of the use of collected thyroid cells only if the samples had specific diagnostic and eligibility requirements, for instance the use of cytology cases with extra slides per patient (as described in FNA sample paragraph) in order to have extra slides to keep in the archive for the patient and for medical-legal issues.

We also specified in the methods section that the verbal consent was approved by the Internal Review Board of the University of Pisa.

Kind Regards,

Federica Panebianco, Ph.D.
Postdoctoral Associate
University of Pittsburgh
Department of Pathology
200 Lothrop St, Pittsburgh, PA 15261
Office Telephone: 412-864-3351
Mobile: 412-304-5614
panebiancof@umpc.edu